DOI: 10.37421/2577-0543.2023.7.146
Formulation science plays a pivotal role in optimizing drug delivery systems to enhance the bioavailability and therapeutic efficacy of pharmaceutical compounds. The effective design of drug formulations has the potential to overcome various challenges such as poor solubility, stability, and limited absorption, thus revolutionizing the pharmaceutical industry. In recent years, significant advances in formulation science have paved the way for novel approaches that maximize bioavailability, ensuring that drugs reach their intended targets with greater precision and efficiency. This article explores the nexus between formulation design and drug delivery, highlighting key advancements that are shaping the future of pharmaceutical development
DOI: 10.37421/2577-0543.2023.7.148
DOI: 10.37421/2577-0543.2023.7.147
DOI: 10.37421/2577-0543.2023.7.149
DOI: 10.37421/2577-0543.2023.7.150
DOI: 10.37421/2577-0543.2024.8.189
The pharmaceutical industry is witnessing a paradigm shift in drug formulation techniques, driven by the quest for enhancing drug efficacy and patient outcomes. One of the critical aspects of this evolution is the focus on bioavailability analysis. Bioavailability, the extent and rate at which a drug enters systemic circulation, plays a pivotal role in determining its therapeutic effectiveness. Recent advancements in bioavailability analysis methodologies have not only enabled a deeper understanding of drug absorption kinetics but also paved the way for the development of more efficient and patient-friendly formulations. This article explores the key innovations in bioavailability analysis and their implications for drug formulation revolution. Before delving into advancements, it's crucial to grasp the concept of bioavailability. When a drug is administered, it undergoes various processes such as dissolution, absorption, metabolism and excretion. Bioavailability refers to the fraction of the administered dose that reaches systemic circulation unchanged and the rate at which it reaches the target site. Factors such as drug formulation, route of administration and patient-specific variables influence bioavailability.
DOI: 10.37421/2577-0543.2024.8.188
The optimization of drug delivery is crucial for improving therapeutic outcomes in pharmaceutical sciences. This article explores formulation techniques and bioavailability evaluation methods essential for refining drug delivery systems. Nanoformulations like nanoparticles, liposomes, and micelles offer benefits such as increased solubility and targeted delivery. Lipid-based delivery systems, such as nanoemulsions and solid lipid nanoparticles, utilize lipids to enhance drug absorption and stability. Controlled release systems, prodrug design, and pharmacokinetic studies further optimize drug delivery by modulating release kinetics and improving bioavailability. In vitro-in vivo correlation and advanced imaging techniques provide precise evaluation of drug bioavailability and distribution. Integrating formulation science and bioavailability assessment promises the development of safer more effective drug delivery systems, advancing pharmaceutical innovation for improved patient care.
DOI: 10.37421/2577-0543.2024.8.190
Drug development is a complex and meticulous process that requires numerous steps to bring a new therapeutic agent from conception to the market. Among the pivotal stages is formulation engineering and bioavailability analysis, where the drug is crafted into a viable product with optimal efficacy and safety profiles. This article delves into the crucial steps involved in these processes and highlights their significance in the pharmaceutical industry. Formulation engineering involves the art and science of designing a drug product that ensures stability, efficacy and patient compliance. It begins with selecting appropriate drug candidates and excipients, followed by optimizing the formulation to achieve the desired therapeutic outcome. Several factors influence formulation design, including the physicochemical properties of the drug, route of administration, and intended dosage form.
DOI: 10.37421/2577-0543.2024.8.191
Formulation challenges are ubiquitous in the pharmaceutical industry, often posing significant hurdles in the development of effective drug delivery systems. Among these challenges, optimizing bioavailability stands out as a paramount objective. Bioavailability, the fraction of administered drug that reaches systemic circulation, profoundly influences a drug's therapeutic efficacy and clinical outcomes. In this article, we explore the evolving landscape of bioavailability evaluation and the innovative strategies revolutionizing drug formulation to overcome these challenges. Bioavailability is a multifaceted concept influenced by various factors such as drug solubility, permeability, metabolism, and formulation characteristics. It is a critical determinant of a drug's pharmacokinetic profile, influencing its onset of action, duration of effect, and overall therapeutic response. Poor bioavailability can lead to suboptimal drug concentrations at the target site, resulting in therapeutic failure or increased risk of adverse effects.
DOI: 10.37421/2577-0543.2024.8.192
DOI: 10.37421/2577-0543.2024.8.193
DOI: 10.37421/2577-0543.2024.8.194
DOI: 10.37421/2577-0543.2024.8.195
DOI: 10.37421/2577-0543.2024.8.196
DOI: 10.37421/2577-0543.2024.8.197
Heyam Saad Ali
In pharmacology, bioavailability is a subcategory of retention and is the portion of a directed portion of unaltered medication that arrives at the fundamental dissemination, one of the head pharmacokinetic properties of medications. By definition, when a drug is regulated intravenously, its bioavailability is 100%. Bioavailability (BA) is a term utilized in pharmacology and nourishing and ecological sciences. In pharmacology, it alludes to the degree and rate at which a directed medication is consumed by the body's circulatory framework, the foundational flow. A near bioavailability study alludes to the examination of bio availabilities of various definitions of a similar medication or distinctive medication items, Oral bioavailability (F%) is the portion of an oral controlled medication that arrives at fundamental flow. After intravenous organization, a medication is legitimately and completely accessible in the circulatory system and can be conveyed using fundamental flow to the point where a pharmacological impact happens. Bioavailability is the degree to which a nutrient is available to the body for use and measures the rate that a supplement is absorbed within the body after it has been administered. Just because you take a certain dose of a product, doesn't always mean that is exactly what your body will receive.
Heyam Saad Ali
Heyam Saad Ali
It’s an enormous pleasure and feel respected to organize 11th World Congress on Bioavailability and Bioequivalence scheduled during November 26-27, 2020 at Istanbul, Turkey. The conference is mainly focused on the theme of “The rationale of BA/BE studies for Pharmaceutical business and Public health”.
BABE 2020 is designed with the keynote sessions, session lectures, poster presentations, presentations from the young researchers, panel Discussions, and the B2B meetings with world-renowned speakers from the stream of clinical and pharmaceutical sciences. It provides the best platform for the researchers to the researchers all over globe to introduce themselves to the innovative world with their unique research. Its an open forum to discuss new researches and the challenges faced during the BA/BE studies, manufacturing the generic drugs and their effect on the public health.
To give Pregabalin (Lyrica) 75 mg 2 h or more before surgery then 75 mg
QHS for 3 days postoperative, to be reassessed by acute pain service team if extension needed. Then add Celecoxib (if not
contraindicated) 200-400 mg tablet 1 h before surgery then 200 mg BID for 3 days only
Drug delivery through the oral mucous film is considered to be a promising contrasting option to the oral course.
Sublingual course is a quick onset of activity and preferred patient consistence over orally ingested tablets. Sublingual
(contracted SL), from the Latin for "under the tongue", alludes to the pharmacological course of organization by which drugs
diffuse into the blood through tissues under the tongue.
Because interdentally and sub gingival sites are relatively inaccessible to mouth-rinsing, they necessitate alternative methods of application of antiplaque chemicals. a spread of home care aids, including brushes, floss and tooth picks are wont to apply antiplaque agent interdentally. Morgh and Bjorvan used toothpicks to hold sodium and amine fluoride to the tooth surface and Newbrun found that iodine impregnated floss reduced the proportion of streptococcus mutans in approximal plaque quite plain floss. Fluoride containing floss has been shown to scale back bacterial growth chlorhexidine impregnanted floss was found to supply greater decrease in plaque than untreated floss.
Starch nanoparticles were prepared in this novel IL/O microemulsion with OSA maize starch as the raw material, epichlorohydrin as the crosslinker and characterized by Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM) and DLS. Finally, drug loading and releasing properties of starch nanoparticles were investigated with indomathacin as a drug model
Ketamine has been broadly wont to give absence of pain in consume dressing changes, amid extraction and uniting and for sedation. It’s an interesting part in rehashed soporifics for consumes dressings. It’s the foremost affective operator for IM organization in patients with broad burns where there a trouble finds an appropriate vein.
Esketamine drug is employed within the treatment of restrictive depression
in adults. In 1997 Esketamine is introduced in medical use and now in March
5th, 2019 it's approved by FDA for the treatment of depression in adults by
nasal route. Oneamong good advantage of Nasal Spray is that it'll act faster
and potentially help those patients which experience suicidal thoughts more
quickly. it's the non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist and up to some extent it'll also act on dopamine reuptake inhibitor
but don't interact with sigma receptor as like ketamine drug. it's a sort of
ketamine drug which is approved by FDA in 1970 which having two chemical
forms R and S and Esketamine contain on of it and that i .e. S form.
Journal of Formulation Science & Bioavailability received 23 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 